The alternative pathway of complement activation provides nonimmune recognition of microorganisms and altered mammalian cells leading to host defense reactions of opsonization, cytolysis, and inflammation. In human serum the alternative pathway can be activated by bacterial and fungal cell wall materials, by virus-infected human cells, and by some mammalian erythrocytes. Although the chemical characteristics required for activation have not been defined, particulate activators share the ability to provide sites for the formation of the alternative pathway C3 convertase which are protected from serum regulatory proteins. Changes in mammalian cell surfaces such as removal of sialic acid from erythrocytes can influence their ability to serve this protective function. We have found that model lipid membranes in the form of liposomes can activate complement by the alternative pathway and that changes in composition affect this ability. Since the composition of the liposomes is defined and easily modified, they provide a simple model with which to study the role of membrane lipids in alternative pathway activation. We propose to use this model to study the influence of particular membrane lipids and glycolipids on the formation and regulation of the C3 convertase. We will determine which lipids provide binding sites for C3 and which interact with the control proteins (Beta1H and C3b inactivator). We will study the role of viral glycoproteins in activation by measles-infected cells by incorporating purified viral and cell membrane glycoproteins into liposomes and measuring alternative pathway activation. These studies will increase our knowledge of the membrane determinants of the alternative pathway recognition system. The findings will add to our understanding of host defense against bacterial and viral infection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI024720-02
Application #
3137917
Study Section
Allergy and Immunology Study Section (ALY)
Project Start
1986-09-01
Project End
1988-08-31
Budget Start
1987-09-01
Budget End
1988-08-31
Support Year
2
Fiscal Year
1987
Total Cost
Indirect Cost
Name
University of New Mexico
Department
Type
Schools of Medicine
DUNS #
829868723
City
Albuquerque
State
NM
Country
United States
Zip Code
87131
Crowell, R E; Hallin, G; Heaphy, E et al. (1995) Hyperoxic suppression of Fc-gamma receptor-mediated phagocytosis by isolated murine pulmonary macrophages. Am J Respir Cell Mol Biol 12:190-5
Reilly, B D; Makrides, S C; Ford, P J et al. (1994) Quantitative analysis of C4b dimer binding to distinct sites on the C3b/C4b receptor (CR1). J Biol Chem 269:7696-701
Wang, R H; Phillips Jr, G; Medof, M E et al. (1993) Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients. J Clin Invest 92:1326-35
Hicks, P S; Saunero-Nava, L; Du Clos, T W et al. (1992) Serum amyloid P component binds to histones and activates the classical complement pathway. J Immunol 149:3689-94
Crowell, R E; Du Clos, T W; Montoya, G et al. (1991) C-reactive protein receptors on the human monocytic cell line U-937. Evidence for additional binding to Fc gamma RI. J Immunol 147:3445-51
Mold, C; Walter, E I; Medof, M E (1990) The influence of membrane components on regulation of alternative pathway activation by decay-accelerating factor. J Immunol 145:3836-41
Mold, C (1989) Effect of membrane phospholipids on activation of the alternative complement pathway. J Immunol 143:1663-8
Mold, C; Nemerow, G R; Bradt, B M et al. (1988) CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells. J Immunol 140:1923-9
Mold, C; Bradt, B M; Nemerow, G R et al. (1988) Activation of the alternative complement pathway by EBV and the viral envelope glycoprotein, gp350. J Immunol 140:3867-74
Mold, C; Bradt, B M; Nemerow, G R et al. (1988) Epstein-Barr virus regulates activation and processing of the third component of complement. J Exp Med 168:949-69

Showing the most recent 10 out of 12 publications